{"id":"placebo-of-dapagliflozin","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A placebo is an inert substance used as a control in clinical trials to establish the true efficacy of the active drug (dapagliflozin) by comparison. Patients receiving placebo will experience no pharmacological effect from the study treatment itself, allowing researchers to measure the actual therapeutic benefit of dapagliflozin against baseline disease progression and placebo response.","oneSentence":"This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:13.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in dapagliflozin clinical trial (indication depends on parent trial)"}]},"trialDetails":[{"nctId":"NCT06742723","phase":"PHASE3","title":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-03","conditions":"Chronic Kidney Disease and Hypertension","enrollment":5000},{"nctId":"NCT07488689","phase":"PHASE3","title":"Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-07","conditions":"Septic Shock","enrollment":568},{"nctId":"NCT06307652","phase":"PHASE3","title":"Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-12","conditions":"Heart Failure and Impaired Kidney Function","enrollment":4800},{"nctId":"NCT06364930","phase":"PHASE4","title":"SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-03-26","conditions":"Chronic Hepatitis B","enrollment":412},{"nctId":"NCT07273838","phase":"PHASE2","title":"Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-03-05","conditions":"Heart Failure, Acute Kidney Injury","enrollment":130},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT03269058","phase":"PHASE4","title":"Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2017-12-20","conditions":"Type-2 Diabetes, Oral Antidiabetics","enrollment":28},{"nctId":"NCT07222917","phase":"PHASE2","title":"A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-05","conditions":"Chronic Kidney Disease and Hypertension","enrollment":218},{"nctId":"NCT06785116","phase":"PHASE4","title":"A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-03-02","conditions":"Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia","enrollment":200},{"nctId":"NCT07280585","phase":"PHASE3","title":"STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2025-12-16","conditions":"Polycystic Kidney, Autosomal Dominant","enrollment":420},{"nctId":"NCT07025629","phase":"PHASE3","title":"Dapagliflozin for Cardio-renal Protection After ICU Discharge","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-02","conditions":"Heart Failure and Chronic Kidney Disease Post-ICU","enrollment":600},{"nctId":"NCT07405216","phase":"PHASE4","title":"Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Centenario Hospital Miguel Hidalgo","startDate":"2026-03-01","conditions":"Chronic Kidney Disease (Mild to Moderate), Albuminuria, Adolescent","enrollment":200},{"nctId":"NCT06174753","phase":"PHASE3","title":"Dapagliflozin in STEMI","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2025-01-20","conditions":"ST Elevation Myocardial Infarction, Myocardial Infarction","enrollment":256},{"nctId":"NCT06677060","phase":"PHASE3","title":"Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-14","conditions":"Heart Failure","enrollment":11300},{"nctId":"NCT05139914","phase":"PHASE4","title":"Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Boston University","startDate":"2022-05-31","conditions":"Diabetes Mellitus, Type 2, Endothelial Dysfunction","enrollment":4},{"nctId":"NCT07323524","phase":"PHASE4","title":"Dapagliflozin in Active Lupus Nephritis","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-01","conditions":"Lupus Nephritis (LN)","enrollment":33},{"nctId":"NCT04930549","phase":"PHASE2","title":"Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2022-10-18","conditions":"Renal Insufficiency, Chronic","enrollment":32},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT07379333","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"NOT_YET_RECRUITING","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2026-02","conditions":"Type 2 Diabetes","enrollment":118},{"nctId":"NCT06268873","phase":"PHASE3","title":"A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-29","conditions":"Chronic Kidney Disease and Hypertension","enrollment":2554},{"nctId":"NCT05179356","phase":"PHASE2","title":"Dapagliflozin in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Mads Ersbøll","startDate":"2023-01-01","conditions":"Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension","enrollment":52},{"nctId":"NCT06269484","phase":"PHASE2","title":"A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-15","conditions":"Liver Cirrhosis","enrollment":73},{"nctId":"NCT06772168","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia","status":"RECRUITING","sponsor":"CMG Pharmaceutical Co. Ltd","startDate":"2024-04-19","conditions":"Dyslipidemia, Type 2 Diabetes","enrollment":240},{"nctId":"NCT07344922","phase":"PHASE3","title":"SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-09-01","conditions":"Chronic Kidney Disease, Anemia, Cardiovascular Calcification","enrollment":100},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":"AMI, STEMI, NSTEMI","enrollment":450},{"nctId":"NCT07174687","phase":"PHASE2","title":"SGLT2 Inhibitors in Geographic Atrophy","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-12-02","conditions":"Retinal Degeneration, Retinal Diseases, Eye Diseases","enrollment":70},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT05374291","phase":"PHASE3","title":"The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2022-11-08","conditions":"Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure","enrollment":1750},{"nctId":"NCT07239011","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Depression","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Depression","enrollment":60},{"nctId":"NCT07245069","phase":"PHASE2","title":"Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-02-01","conditions":"Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD)","enrollment":100},{"nctId":"NCT07056699","phase":"PHASE3","title":"SGLT2i, Pioglitazone, and Ketone Production in T1D","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-01-30","conditions":"Type1diabetes","enrollment":24},{"nctId":"NCT06762964","phase":"PHASE2","title":"CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-05-16","conditions":"Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction","enrollment":27},{"nctId":"NCT07026968","phase":"PHASE3","title":"A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2025-06-20","conditions":"Type 2 Diabetes","enrollment":815},{"nctId":"NCT06639087","phase":"PHASE1","title":"A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-09-27","conditions":"Renal Impairment, Heart Failure","enrollment":8},{"nctId":"NCT06888505","phase":"PHASE2","title":"Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2024-09-01","conditions":"Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity","enrollment":90},{"nctId":"NCT05468203","phase":"PHASE3","title":"PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care","status":"RECRUITING","sponsor":"The George Institute","startDate":"2023-11-29","conditions":"Acute Kidney Injury","enrollment":3000},{"nctId":"NCT06647745","phase":"PHASE3","title":"A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension","status":"RECRUITING","sponsor":"THPharm Corp.","startDate":"2025-04-10","conditions":"Type 2 Diabetes, Hypertension","enrollment":221},{"nctId":"NCT07147114","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)","status":"NOT_YET_RECRUITING","sponsor":"Gachon University Gil Medical Center","startDate":"2025-10-31","conditions":"Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH, HFmrEF","enrollment":64},{"nctId":"NCT06922656","phase":"PHASE4","title":"Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?","status":"NOT_YET_RECRUITING","sponsor":"Dasman Diabetes Institute","startDate":"2025-09-15","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT05762952","phase":"PHASE1","title":"Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2023-06-06","conditions":"Myocardial Ischemia","enrollment":40},{"nctId":"NCT05516498","phase":"PHASE2","title":"Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-10-31","conditions":"Liver Cirrhosis","enrollment":205},{"nctId":"NCT06054035","phase":"PHASE4","title":"SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-10-26","conditions":"Type2diabetes, PreDiabetes, Renal Failure","enrollment":170},{"nctId":"NCT07070765","phase":"NA","title":"Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity","status":"NOT_YET_RECRUITING","sponsor":"University of Aberdeen","startDate":"2025-11-01","conditions":"Breast Cancer","enrollment":70},{"nctId":"NCT01439854","phase":"NA","title":"Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-03","conditions":"Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome","enrollment":18},{"nctId":"NCT03878459","phase":"PHASE4","title":"Dapagliflozin Plus Pioglitazone in T1DM","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-08-08","conditions":"Type 1 Diabetes Mellitus","enrollment":120},{"nctId":"NCT04591639","phase":"NA","title":"The DAPA-MEMRI Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-08-19","conditions":"Heart Failure, Diabetic Cardiomyopathies","enrollment":160},{"nctId":"NCT04363697","phase":"PHASE4","title":"Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-09-24","conditions":"Acute Heart Failure, Heart Failure","enrollment":2401},{"nctId":"NCT03919656","phase":"PHASE4","title":"SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2019-05-12","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT07020377","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amira Bisher,PhD","startDate":"2024-01-15","conditions":"Diabetes Mellitus, Non Alcholic Fatty Liver Disease","enrollment":60},{"nctId":"NCT06140537","phase":"PHASE4","title":"Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-02-01","conditions":"Kidney Transplant; Complications, Vascular Diseases, Diabetes","enrollment":80},{"nctId":"NCT05590143","phase":"PHASE4","title":"proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC","startDate":"2023-06-09","conditions":"Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor","enrollment":784},{"nctId":"NCT06350123","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-05-01","conditions":"Chronic Kidney Disease","enrollment":324},{"nctId":"NCT05884866","phase":"PHASE2","title":"A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.","status":"RECRUITING","sponsor":"Klinikum Nürnberg","startDate":"2023-07-13","conditions":"Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis, Chronic Kidney Disease Stage 3","enrollment":100},{"nctId":"NCT05570305","phase":"PHASE2","title":"Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2022-10-06","conditions":"Chronic Kidney Diseases","enrollment":42},{"nctId":"NCT06286878","phase":"PHASE2, PHASE3","title":"Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2021-12-08","conditions":"Myocardial Infarction, Acute Coronary Syndrome, Diabetes","enrollment":80},{"nctId":"NCT06750458","phase":"PHASE3","title":"Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-08-20","conditions":"Glioma, Dapagliflozin (Forxiga), Dexamethasone","enrollment":75},{"nctId":"NCT05748925","phase":"PHASE4","title":"Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-10-01","conditions":"SLE, Lupus Nephritis, SGLT2 Inhibitors","enrollment":84},{"nctId":"NCT05852704","phase":"PHASE3","title":"SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-04","conditions":"Chronic Coronary Syndrome, Atrial Fibrillation","enrollment":800},{"nctId":"NCT03899402","phase":"PHASE2, PHASE3","title":"Triple Therapy in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2019-05-01","conditions":"Type 1 Diabetes Mellitus","enrollment":78},{"nctId":"NCT05998837","phase":"PHASE2, PHASE3","title":"GLUcose Transport and REnalPROtection in Chronic Kidney Disease","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2021-04-13","conditions":"Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension","enrollment":34},{"nctId":"NCT06000462","phase":"PHASE4","title":"The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2024-04-22","conditions":"Obesity, Dapagliflozin Adverse Reaction, Weight Loss","enrollment":150},{"nctId":"NCT04965935","phase":"PHASE3","title":"Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2021-07-15","conditions":"Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes","enrollment":52},{"nctId":"NCT05743907","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-04-25","conditions":"Diabetes Mellitus","enrollment":231},{"nctId":"NCT04564742","phase":"PHASE3","title":"Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-22","conditions":"Acute Myocardial Infarction, Heart Failure","enrollment":4017},{"nctId":"NCT05795400","phase":"NA","title":"Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2022-06-01","conditions":"Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction","enrollment":50},{"nctId":"NCT06615674","phase":"PHASE4","title":"Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Yoga Yudhistira","startDate":"2024-09-21","conditions":"Acute Myocardial Infarction (AMI), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","enrollment":40},{"nctId":"NCT06619600","phase":"PHASE3","title":"Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Clinic of Barcelona","startDate":"2021-05-30","conditions":"ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Heart Failure","enrollment":54},{"nctId":"NCT06820567","phase":"PHASE3","title":"Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-03-01","conditions":"Chronic Kidney Diseases, Diabetes Type 2","enrollment":210},{"nctId":"NCT05359263","phase":"PHASE2","title":"Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD","status":"RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2022-06-08","conditions":"Chronic Kidney Diseases","enrollment":222},{"nctId":"NCT05459701","phase":"PHASE4","title":"Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2022-05-01","conditions":"Nonalcoholic Fatty Liver Disease, Type 2 Diabetes","enrollment":50},{"nctId":"NCT06759909","phase":"PHASE1","title":"Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-01-03","conditions":"Dapagliflozin (Forxiga), Atrial Fibrillation (AF)","enrollment":100},{"nctId":"NCT04492722","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-10-01","conditions":"Chronic Kidney Disease","enrollment":613},{"nctId":"NCT06740786","phase":"NA","title":"Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation","status":"NOT_YET_RECRUITING","sponsor":"Xu Liu","startDate":"2024-12-10","conditions":"Atrial Fibrillation (AF)","enrollment":250},{"nctId":"NCT05944016","phase":"PHASE3","title":"Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients","status":"RECRUITING","sponsor":"University Hospital Goettingen","startDate":"2024-03-25","conditions":"Chronic Kidney Failure in Children and Young Adults","enrollment":102},{"nctId":"NCT04234867","phase":"PHASE1","title":"Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)","status":"TERMINATED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2022-05-18","conditions":"Type 1 Diabetes, Diabetic Ketoacidosis","enrollment":2},{"nctId":"NCT06304857","phase":"PHASE3","title":"CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL","status":"RECRUITING","sponsor":"4th Military Clinical Hospital with Polyclinic, Poland","startDate":"2024-04-15","conditions":"Breast Cancer, Heart Failure","enrollment":188},{"nctId":"NCT04792190","phase":"PHASE4","title":"Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2021-07-27","conditions":"Atrial Fibrillation","enrollment":25},{"nctId":"NCT06711185","phase":"PHASE3","title":"Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy","status":"RECRUITING","sponsor":"University of Campinas, Brazil","startDate":"2024-01-30","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT05424315","phase":"PHASE2, PHASE3","title":"Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients","status":"COMPLETED","sponsor":"Omar Younis","startDate":"2021-10-01","conditions":"Anterior MI","enrollment":100},{"nctId":"NCT04869124","phase":"PHASE4","title":"Dapagliflozin on Volume Vascular Outcomes.","status":"COMPLETED","sponsor":"Frank Ruschitzka","startDate":"2021-02-15","conditions":"Heart Failure，Congestive","enrollment":80},{"nctId":"NCT05735197","phase":"PHASE4","title":"Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-09-01","conditions":"Chronic Kidney Diseases, Bone Diseases, Metabolic","enrollment":100},{"nctId":"NCT02987738","phase":"PHASE1","title":"Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2017-02-09","conditions":"Type1diabetes","enrollment":30},{"nctId":"NCT05305911","phase":"PHASE2","title":"Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI","status":"RECRUITING","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2022-08-03","conditions":"Heart Attack, Enlarged Heart","enrollment":81},{"nctId":"NCT05321706","phase":"PHASE3","title":"DAPAgliflozin for Renal Protection in Heart Transplant Recipients","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2022-06-08","conditions":"Heart Transplant Failure, Kidney Failure","enrollment":430},{"nctId":"NCT04743453","phase":"PHASE4","title":"EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-08-17","conditions":"Kidney Transplantation, Diabetes Mellitus, Type 2, Diabetes Complications","enrollment":211},{"nctId":"NCT06373523","phase":"EARLY_PHASE1","title":"MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2024-09-01","conditions":"Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease","enrollment":60},{"nctId":"NCT04724837","phase":"PHASE2","title":"Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-28","conditions":"Chronic Kidney Disease","enrollment":542},{"nctId":"NCT04004793","phase":"PHASE4","title":"Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-06-12","conditions":"Type 2 Diabetes","enrollment":328},{"nctId":"NCT04170543","phase":"PHASE2","title":"A Phase 2b Diabetic Kidney Disease Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-11-18","conditions":"Diabetic Kidney Disease","enrollment":609},{"nctId":"NCT04707261","phase":"PHASE4","title":"Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)","status":"RECRUITING","sponsor":"Xiangtan Central Hospital","startDate":"2021-08-06","conditions":"Anemia, Heart Failure","enrollment":1990},{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT03190694","phase":"PHASE2","title":"Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria","status":"COMPLETED","sponsor":"Hiddo Lambers Heerspink","startDate":"2017-11-12","conditions":"Chronic Kidney Diseases, Proteinuria","enrollment":53},{"nctId":"NCT04249778","phase":"PHASE4","title":"Dapagliflozin at Discharge on Hospital Heart Failure Readmission","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-07-29","conditions":"Heart Failure, Diabetes","enrollment":105},{"nctId":"NCT03801642","phase":"PHASE1, PHASE2","title":"Dapagliflozin In Alzheimer's Disease","status":"COMPLETED","sponsor":"Jeff Burns, MD","startDate":"2019-01-29","conditions":"Alzheimer Disease","enrollment":46},{"nctId":"NCT06442280","phase":"PHASE4","title":"SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF","status":"NOT_YET_RECRUITING","sponsor":"University of Palermo","startDate":"2024-06","conditions":"Heart Failure Acute, Diabetes Type 2, Heart Failure With Reduced Ejection Fraction","enrollment":544},{"nctId":"NCT06434025","phase":"PHASE3","title":"IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-05-24","conditions":"Heart Failure, Systolic, Iron Deficiencies","enrollment":99},{"nctId":"NCT04794517","phase":"PHASE2","title":"Dapagliflozin in Non-diabetic Stage IV CKD","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-11-08","conditions":"Chronic Kidney Diseases","enrollment":32},{"nctId":"NCT05174052","phase":"PHASE3","title":"Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2022-06-01","conditions":"Diabetes Mellitus, Atrial Fibrillation","enrollment":28},{"nctId":"NCT05392959","phase":"PHASE4","title":"Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2022-06-06","conditions":"Diabetes Mellitus, Type 2","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":436,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Dapagliflozin","genericName":"Placebo of Dapagliflozin","companyName":"Hospital de Clinicas de Porto Alegre","companyId":"hospital-de-clinicas-de-porto-alegre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient. Used for Control arm in dapagliflozin clinical trial (indication depends on parent trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}